NCT06405464

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures

Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study: Uptake, Outcome, and Risk Factors for Treatment Failures in a Real-world Setting

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 600 (estimated)
• Sponsor: University of Zurich · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to characterize Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen, assess adherence to Swiss label indications, and describe treatment outcomes in this large, multicentre, heterogeneous, high-income setting. Moreover, the study aims to assess virological, immunological, demographic, clinical, and behavioural factors associated with viral failure under CAB+RPV LA regimen.

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	VOCABRIA 30Mg Tablet	CAB 30 mg Film-coated tablets
DRUG	EDURANT 25Mg Tablet	RPV 25 mg film-coated tablets
DRUG	Cabotegravir Injectable Suspension	CAB LA 600 mg prolonged release suspension for injection (3 mL)
DRUG	Rilpivirine Injectable Suspension	RPV LA 900 mg prolonged release suspension for injection (3 mL)
BIOLOGICAL	Intact proviral DNA assay	HIV-1 latent reservoir size
BIOLOGICAL	Full-length sequencing	Proviral DNA

Timeline

• Start date: 2022-03-01
• Primary completion: 2025-12-31
• Completion: 2026-06-30
• First posted: 2024-05-08
• Last updated: 2024-05-08

Locations

1 site across 1 country: Switzerland